Aktienanalyse zu XBiotech Inc (XBIT)XBITXBiotech Inc

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products, including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

XBiotech Inc. is not a good buy right now due to significant ongoing losses and negative performance trends. The current price is $2.27, with a year-to-date change of -4.62% and a one-year change of -24.83%. The company reported a loss of $6.7 million in Q2 2026, which translates to a per-share loss of $0.22, indicating persistent financial challenges. The RSI is at 38.971, suggesting that the stock is nearing oversold territory but is not yet a buy signal. The main risk is the company's negative earnings trajectory, with a forward P/E of 0 and a price-to-sales ratio of 233.74, indicating overvaluation relative to sales.